We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and Terms of Use Accept Cookie Settings Logo for Karyopharm Main Menu Inspired by Patients, Every day. LEARN MORE ABOUT KARYOPHARM XPO1 Inhibition & SINE Technology LEARN MORE ABOUT OUR TECHNOLOGY Karyopharm Pipeline LEARN MORE ABOUT OUR PIPELINE Our Commitment to Patients LEARN MORE ABOUT PATIENTS WHO INSPIRE US Karyopharm Clinical Trials LEARN MORE ABOUT OUR CLINICAL TRIALS Tweets NOVEMBER 25, 2021 Karyopharm wishes our entire community a very Happy Thanksgiving! May your day be filled with love, gratitude, and… https://t.co/c8WsUJPvpe Twitter 1 day ago NOVEMBER 20, 2021 LA! Be sure to check out @theMMRF Team for Cures 5k on November 21st at Griffith Park! Karyopharm is a proud suppor… https://t.co/cTB6AVRHid Twitter 5 days ago NOVEMBER 19, 2021 Tomorrow, @IMFmyeloma hosts its Regional Community Workshop where needs specific to myeloma communities in Florida… https://t.co/eSql8gphak Twitter 1 week ago TWITTER FEED Press Releases NOVEMBER 11, 2021 Karyopharm to Participate at Jefferies London Healthcare Conference NOVEMBER 4, 2021 Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition NOVEMBER 3, 2021 Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights VIEW ALL Investor Events THURSDAY, NOVEMBER 18, 2021 3:00AM EST Jefferies London Healthcare Conference 2021 WEDNESDAY, NOVEMBER 3, 2021 8:30AM – 9:30AM EDT Karyopharm Therapeutics 3Q21 Earnings Call TUESDAY, SEPTEMBER 14, 2021 2:00PM EDT Baird 2021 Global Healthcare Conference MONDAY, SEPTEMBER 13, 2021 11:00AM EDT Morgan Stanley 19th Annual Global Healthcare Conference VIEW ALL RECENT MEDICAL CONFERENCES ASH 2021: Karyopharm Presentations and Posters December 11 – 14, Atlanta, Georgia VIEW ALL DETAILS HERE Join The Karyopharm Team “As the VP of Data Sciences, the role of my team and of myself is to advance Karyopharm drug discovery and development programs by utilizing our knowledge in data. Throughout my four years at the company, I have been able to work on all of our clinical studies and regulatory submissions. These types of opportunities to help patients with unmet medical needs makes me realize that my work is so meaningful and so important.” “It means a lot to a scientist like me who can help a company develop a drug and hopefully get it approved to be able to reach the cancer patients who need it most – every day we try to transition science into development, turn strategy into execution, and ultimately try to turn a molecule into a pill that can help treat multiple cancers.” Hongmei Executive Director, Clinical Pharmacology & DMPK LEARN MORE © Karyopharm, 2021. All Rights Reserved. Terms of Use Privacy Policy Site Map NEW INTERIM PHASE 2 SELINEXOR DATA IN MYELOFIBROSIS SELECTED FOR ORAL PRESENTATION AT ASH 2021 VIEW FULL PRESS RELEASE Close